Epoprostenol sodium drug is used in human vascular tissue. It is acidic in nature with molecular weight of 374.45 and is used to treat pulmonary hypertension. This drug is also used in clinical research and diagnosis. It belongs to the well-known class of drug called vasodilators which helps in improving tiredness, shortness of breath, and infection.
Epoprostenol sodium drug is used in healthcare sector for blood thinning and thus prevents blood clotting. Its haemodynamic effects are also used to delay the need for transplant surgery. Therefore, its demand has been consistently rising in the healthcare sector thereby facilitating the growth of the market. Apart from this, cost effectiveness is another factor which is driving the growth of this market.
Request For Report Sample with Table of [email protected] https://www.researchreportinsights.com/report/upsample/120124903/Epoprostenol-Sodium-Drugs-Market
However, usage of epoprostenol sodium drug have some side-effects like chest pain, headache, bone pain, slow heart-beat rate, muscle pain, stomach pain, anxiety, nausea, jaw pain, hypotension, nervousness, vomiting, and dizziness. Yet, growing need of high quality epoprostenol drug to improve survival and quality of life is expected to reduce the impact of the limitation during the forecast period.
Although, Epoprostenol sodium drug is being preferred in several healthcare applications, it is anticipated to find increased opportunities in treating pulmonary arterial hypertension (PAH) in several countries across the world. In this case, it widens the blood vessels in lungs and lowers the blood pressure.
Global epoprostenol sodium drugs market can be segmented on the basis of type, product type, application, and region. By type, the epoprostenol sodium drug market can be segmented into purity greater than 98% and purity less than 98%. By type, the epoprostenol sodium drugs market can be segmented into 0.5 mg and 1.5 mg. By application, the epoprostenol sodium drugs market can be segmented into injection and others. On the basis of region, the epoprostenol sodium drugs market can be segmented into Europe, North America, Asia Pacific, Middle East and Africa and South America. Amongst all, Europe is expected to be the most lucrative epoprostenol sodium drug market owing to favorable government initiatives and increasing demand in drug development in the region. In Europe, U.K. and Germany are anticipated to hold a significant market share throughout the forecast period and drie its growth.
Key players operating in the global epoprostenol sodium drugs market include Sun Pharmaceutical Industries Ltd., Pfizer CentreOne, Inc., Sanofi SA, Ausun Pharmaceutical Co. Ltd, Actelion Pharms Ltd, and Glaxosmithkline Llc, among others.